The Clozaril National Registry (CNR) is the benchmark for safety of patients being treated with Clozaril® (clozapine). The registry was developed in 1989 in response to a FDA mandate for the monitoring and databasing of White Blood Cell (WBC) counts. On May 12, 2005, the FDA expanded the requirements to include monitoring and databasing of Absolute Neutrophil Counts (ANC). This decision was based on information supplied by the CNR and other global registries.

The CNR's diligence and commitment to patient safety in WBC monitoring has shown that there is an agranulocytosis rate associated with Clozaril therapy of less than 3 per 1,000 patient years during the first 6 months.

The CNR associates are readily available from Monday through Friday, 8:30am-8:00pm Eastern Time with after hours coverage for all other times including holidays. These customer CARE associates are the treating healthcare professionals' resource for referrals to medical information and safety reporting within Novartis Pharmaceuticals Corporation.

Our customer CARE associates' commitment to patient safety includes Clozaril brand clozapine and extends to generic clozapine, with the maintenance of the National Non-Rechallengeable Masterfile (NNRM).

In our continuous commitment to excellence for patient safety and our desire to exceed the expectation of our healthcare professional customers, we have developed a highly efficient web based application. CARE (Clozaril Administration Registry and Enrollment) is an interactive tool for the healthcare professional that interfaces with our CARE associates to deliver unparalleled expedient service.